Article
Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies.
Expert review of hematology - 1 Jul 2017
Finazzi Maria Chiara, Lussana Federico, Salmoiraghi Silvia, Spinelli Orietta, Rambaldi Alessandro
Abstract excerpt
INTRODUCTION: Myelofibrosis (MF) is the most aggressive form among Philadelphia negative (Ph-) myeloproliferative neoplasms (MPNs). In the last years, the mutational landscape of MF has expanded remarkably by the identification of additional recurrent mutations, called subclonal mutations. Areas covered: Here we describe the available data about the currently identified subclonal mutations and their prognostic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.